BioNTech SE [NASDAQ: BNTX] closed the trading session at $286.26 on 07/26/21. The day’s price range saw the stock hit a low of $276.68, while the highest price level was $297.7299. The company report on July 26, 2021 that BioNTech Provides Update on Plans to Develop Sustainable Solutions to Address Infectious Diseases on the African Continent.
BioNTech aims to develop the first mRNA-based vaccine for Malaria prevention with the initiation of a clinical trial by end of 2022.
BioNTech is evaluating sustainable mRNA vaccine production capacities in Africa; the Company’s efforts are supported by the joint convening powers of the World Health Organization (WHO) and the Africa Centers for Disease Control and Prevention (Africa CDC).
The stocks have a year to date performance of 251.15 percent and weekly performance of 17.98 percent. The stock has been moved at 158.80 percent over the last six months. The stock has performed 25.67 percent around the most recent 30 days and changed 63.90 percent over the most recent 3-months.
If compared to the average trading volume of 3.12M shares, BNTX reached to a volume of 4012556 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about BioNTech SE [BNTX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BNTX shares is $195.09 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BNTX stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wolfe Research have made an estimate for BioNTech SE shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on July 19, 2021. The new note on the price target was released on June 16, 2021, representing the official price target for BioNTech SE stock. Previously, the target price had yet another raise to $173, while Goldman analysts kept a Neutral rating on BNTX stock. On May 11, 2021, analysts increased their price target for BNTX shares from 135 to 206.
The Average True Range (ATR) for BioNTech SE is set at 14.64, with the Price to Sales ratio for BNTX stock in the period of the last 12 months amounting to 23.39. The Price to Book ratio for the last quarter was 23.46, with the Price to Cash per share for the same quarter was set at 4.36.
BNTX stock trade performance evaluation
BioNTech SE [BNTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 17.98. With this latest performance, BNTX shares gained by 25.67% in over the last four-week period, additionally plugging by 158.80% over the last 6 months – not to mention a rise of 240.10% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BNTX stock in for the last two-week period is set at 76.90, with the RSI for the last a single of trading hit 84.62, and the three-weeks RSI is set at 71.95 for BioNTech SE [BNTX]. The present Moving Average for the last 50 days of trading for this stock 222.20, while it was recorded at 270.80 for the last single week of trading, and 141.10 for the last 200 days.
BioNTech SE [BNTX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and BioNTech SE [BNTX] shares currently have an operating margin of -55.27 and a Gross Margin at +87.76. BioNTech SE’s Net Margin is presently recorded at +3.15.
Return on Total Capital for BNTX is now -23.29, given the latest momentum, and Return on Invested Capital for the company is 1.34. Return on Equity for this stock inclined to 1.55, with Return on Assets sitting at 0.93. When it comes to the capital structure of this company, BioNTech SE [BNTX] has a Total Debt to Total Equity ratio set at 17.51. Additionally, BNTX Total Debt to Total Capital is recorded at 14.90, with Total Debt to Total Assets ending up at 10.36. Long-Term Debt to Equity for the company is recorded at 16.84, with the Long-Term Debt to Total Capital now at 14.33.
Reflecting on the efficiency of the workforce at the company, BioNTech SE [BNTX] managed to generate an average of $8,926 per employee. Receivables Turnover for the company is 4.86 with a Total Asset Turnover recorded at a value of 0.29.BioNTech SE’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.60 and a Current Ratio set at 2.70.
BioNTech SE [BNTX]: Insider Ownership positions
There are presently around $8,542 million, or 14.80% of BNTX stock, in the hands of institutional investors. The top three institutional holders of BNTX stocks are: BAILLIE GIFFORD & CO with ownership of 6,738,012, which is approximately New of the company’s market cap and around 1.18% of the total institutional ownership; PRIMECAP MANAGEMENT CO/CA/, holding 4,821,718 shares of the stock with an approximate value of $1.38 billion in BNTX stocks shares; and PRICE T ROWE ASSOCIATES INC /MD/, currently with $593.96 million in BNTX stock with ownership of nearly 31.755% of the company’s market capitalization.
Positions in BioNTech SE stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 137 institutional holders increased their position in BioNTech SE [NASDAQ:BNTX] by around 12,468,604 shares. Additionally, 94 investors decreased positions by around 4,395,234 shares, while 30 investors held positions by with 12,974,788 shares. The mentioned changes placed institutional holdings at 29,838,626 shares, according to the latest SEC report filing. BNTX stock had 66 new institutional investments in for a total of 9,347,985 shares, while 43 institutional investors sold positions of 1,580,922 shares during the same period.